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Abstract 60 
Cranial growth and development is a complex process which affects the closely related traits of head 61 
circumference (HC) and intracranial volume (ICV). The underlying genetic influences affecting these 62 
traits during the transition from childhood to adulthood are little understood, but might include both age-63 
specific genetic influences and low-frequency genetic variation. To understand these influences, we 64 
model the developmental genetic architecture of HC, showing this is genetically stable and correlated 65 
with genetic determinants of ICV.  Investigating up to 46,000 children and adults of European descent, 66 
we identify association with final HC and/or final ICV+HC at 9 novel common and low-frequency loci, 67 
illustrating that genetic variation from a wide allele frequency spectrum contributes to cranial growth. The 68 
largest effects are reported for low-frequency variants within TP53, with 0.5 cm wider heads in increaser-69 
allele carriers versus non-carriers during mid-childhood, suggesting a previously unrecognized role of 70 
TP53 transcripts in human cranial development. 71 
 72 
  73 
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Introduction 74 
The size and shape of the vertebrate brain is governed by the internal dimensions of the skull. 75 
Across vertebrate evolutionary history, major changes to brain size and proportion have been 76 
accompanied by modifications to skull morphology1,2. This is also true within the lifespan of an 77 
individual, where developmental changes in brain size and shape must be reflected in changing cranial 78 
phenotypes.   79 
Serial measures of maximal head circumference (HC) or occipito-frontal circumference (OFC) 80 
are routinely obtained to monitor children's cranial growth and brain development during the first years of 81 
life and abnormal trajectories may indicate a range of neurological conditions3. In infants and children, 82 
HC is highly correlated with brain volume as measured by MRI studies4,5, especially in 1.7 to 6 year old 83 
children, although its predictive accuracy decreases with progressing age5. Healthy children from around 84 
the world, who are raised in healthy environments and follow recommended feeding practices, have 85 
strikingly similar patterns of growth6. The observation that final HC is largely determined by the age of 6 86 
years in a large study from the UK7 is therefore likely to be valid in multiple populations. In addition, 87 
nutritional status, body size and HC are closely correlated for healthy children during early life, and 88 
become less related after 24 months of age8. While HC properties in early childhood have immediate 89 
medical relevance, there are also compelling reasons to study HC in adulthood. In the adult population 90 
skeletal measures continue to act as a permanent measure of peak brain size that is unaffected by 91 
subsequent atrophic brain changes9. In early childhood, HC is likely to proxy overall body size and timing 92 
of growth, tracking changes in brain size. In older individuals, HC is valuable precisely because HC is 93 
robust to soft tissue atrophy, solely reflecting an absolute measure of final HC dimension.  94 
HC is highly heritable and the notion of a developmentally changing, but etiologically 95 
interrelated, phenotypic expression of HC during the life course is supported by twin studies10. Reported 96 
twin-h2 estimates of 90% in infants, 85–88% in early childhood, 83–87% in adolescence and 75% in 97 
young and mid adulthood10, with evidence for strong genetic stability between mid-childhood and early 98 
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adulthood10. There are arguments to support the hypothesis that some of the underlying genetic factors act 99 
by a coordinated integration of signaling pathways regulating both brain and skull morphogenesis during 100 
development11. Especially, cells of early brain and skull are sensitive to similar signaling families11. 101 
Genetic underpinning of potentially shared mechanisms is supported by the fact that genome-wide signals 102 
for both infant HC and ICV are strengthened when combined12, irrespective of their dissimilar 103 
developmental stages. However, genetic investigations studying (near) final HC and adult ICV are likely 104 
to be more informative on mechanisms underlying developmentally shared growth patterning which 105 
affect final cranial dimension. Additionally, low-frequency genetic variants, ranging between 0.5% to 5% 106 
minor allele frequency, have been poorly characterized by previous genome-wide association study 107 
(GWAS) efforts13, both due to the small size of previous studies, and the limited coverage of lower-108 
frequency markers by the first imputation panels.  109 
Exploiting whole-genome sequence data together with high-density imputation panels such as the 110 
joint UK10K and 1000 genomes (UK10K/1KGP)14 and the haplotype reference consortium (HRC)15, that 111 
have previously facilitated the discovery of low-frequency genetic variants for a range of traits16,17, we 112 
carry out GWAS for final HC. Specifically, we aim to 113 
a)  study low-frequency and common variants for final HC, allowing for age-specific effects through 114 
meta-analyses of mid-childhood and/or adulthood datasets, 115 
b)  investigate genetic variants influencing a combined phenotype of (near) final HC and ICV, 116 
termed final cranial dimension, and 117 
c)  explore developmental changes in the genetic architecture of HC through longitudinal modelling 118 
of genetic variances in unrelated individuals as well as growth curve modelling of HC trajectories for 119 
carriers and non-carriers of high risk variants. 120 
Through these analyses we show that the developmental genetic architecture of HC is genetically 121 
stable during the course of childhood and adolescence and correlates with genetic determinants of ICV. 122 
Integrating information from both (near) final HC and ICV in a combined analysis including  up to 123 
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46,000 children and adults of European descent, we identify  9 novel common and low-frequency loci for 124 
either HC or HC+ICV, including low-frequency variation within TP53. Collectively, these findings 125 
provide insight into the genetic effects influencing cranial growth during childhood and adolescence, 126 
while yielding additional genetic associations which enhance our understanding of the biological 127 
mechanisms underlying these complex developmental processes.   128 
 129 
Results 130 
Genome-wide analysis of HC scores 131 
We carried out genome-wide analysis of HC scores using a two-stage developmentally-sensitive 132 
design (Figure 1a) including (i) pediatric (6 to 9 years of age), (ii) adult (16 to 98 years) and (iii) 133 
combined pediatric and adult samples comprising up to 18,881 individuals of European origin from 11 134 
population-based cohorts and 10 million imputed or sequenced genotypes (Supplementary Table 1). 135 
Inverse-variance weighted meta-analysis (Supplementary Data 1-4, Figure 2a-c, Supplementary Figure 1-136 
3) identified three novel regions at chromosome 4q28.1 (HC (Pediatric): lead variant rs183336048, effect 137 
allele frequency (EAF)=0.02, p=3.0×10-8, Supplementary Figure 5a, 6a), 6p21.32 (HC (Pediatric)/ HC 138 
(Pediatric+adult): lead variant rs9268812, EAF=0.35, p=2.2×10-9, Supplementary Figure 5b, 6b) and 139 
17p13.1 (Pediatric+adult: lead variant rs35850753, EAF=0.02, p=2.0×10-8, Supplementary Figure 5c, 6c, 140 
Figure 3a and b) as associated with HC at an adjusted genome-wide significant level (p<3.3×10-8) (Table 141 
1). We followed-up the two signals in HC (Pediatric+adult) in a further 973 adults of European descent 142 
(mean age 50 years) (Supplementary Table 2, Supplementary Figure 6b,c) and replicated directionally 143 
consistent evidence for association with rs35850753 at the 17p13.1 locus (p=4.5×10-5, Table 1). In the 144 
combined pediatric, adult and follow-up sample, we observed here an increase of 0.24 sex-adjusted SD 145 
units in HC per increase in minor T risk allele (p=2.1×10-10, Table 1, Figure 3a and b). 146 
 147 
 148 
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Growth curve modelling of HC scores between birth and the age of 15 years in participants of the 149 
ALSPAC sample, using a stratified Super Imposition by Translation And Rotation (SITAR) model18, 150 
suggested that carriers of the T risk allele at rs35850753 developed larger heads from mid childhood 151 
onwards (Figure 4), with risk alleles being positively related to individual differences in mean HC (Linear  152 
regression (two-sided) p=6.9x10-12) and HC growth velocity (Linear regression (two-sided) p=7.1x10-11, 153 
Supplementary Table 3). For example, at the age of 10 years male carriers had a HC score of 54.16 cm 154 
and non-carriers a score of 53.63 cm. In comparison, female carriers and non-carriers had a score of 53.21 155 
cm and 52.74 cm respectively. rs3585075 resides within the tumor suppressor encoding TP53 gene and is 156 
not related to any known GWAS locus for HC, ICV or brain volume (Supplementary Table 4, 157 
Supplementary Figure 4) when conducting a conditional analysis, nor any locus affecting height19 158 
(Supplementary Note 2),. In addition to these novel associations, our analysis replicated known signals 159 
for infant HC on chromosome 12q24.3113 and a previously reported joint signal of infant HC and adult 160 
ICV on chromosome 2q32.112 (Figure 2c). 161 
 162 
Applying a gene-based test approach20, multiple HC-associated genes were identified 163 
(Supplementary Data 5-7). The strongest signal in HC (Pediatric), and to a lesser extent in HC 164 
(Pediatric+adult), resides at 12q24.31 (lead gene-wide signal MPHOSPH9, p=2.3x10-10) and contains 165 
single variants in linkage disequilibrium (LD) with known GWAS signals for infant HC13 (e.g. SBNO1, 166 
p= 2.0x10-7). The strongest gene-wide signals that did not harbor variants in LD with known or novel 167 
single GWAS variants were identified at 5q31.3 (lead gene-wide signal SLC4A9 p=6.6x10-9), and at 168 
16p13.3 (lead gene-wide signal E4F1 p=1.6x10-8), using summary statistics from the HC 169 
(Pediatric+adult) meta-analysis. Gene-based analyses were complemented with studies predicting gene 170 
expression levels in multiple tissues (Supplementary Table 5). Notably, for the HC (Pediatric) gene-wide 171 
signal at 6p21.32, including the PRRC2A locus (gene-wide signal p=7.2x10-7, Supplementary Data 5), 172 
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predicted gene expression levels in whole blood were found to be inversely associated with HC scores, 173 
using S-PrediXcan21 software (p= 5.7x10-7; Supplementary Table5, Supplementary Data 8).  174 
 175 
Genetic architecture of HC scores during development 176 
Linkage-disequilibrium score regression (LDSC)22 analyses (Figure 5a, Supplementary Table 6) 177 
using genome-wide summary statistics suggested that heritability estimates during childhood (6 to 9 178 
years) are higher (SNP-h2=0.31(SE=0.05)) than in adult samples (16 to 98 years; SNP-179 
h2=0.097(SE=0.06)), although 95% confidence intervals marginally overlap. The estimated genetic 180 
correlation23 between both developmental windows was high (LDSC-rg=1.04(SE=0.39), p=0.0075). The 181 
LD-score regression intercepts were consistent with one for all HC meta-analyses, suggesting little 182 
inflationary bias in GWAS (Supplementary Table6). 183 
To investigate developmental changes in the genetic architecture of HC scores, we carried out a 184 
multivariate analysis of genetic variances using genetic-relationship-matrix structural equation modelling 185 
(GSEM)24. Fitting a saturated Cholesky decomposition model (Figure 5b) to HC scores assessed in 186 
ALSPAC participants (N=7,924) at the ages of 1.5, 7 and 15 years (Supplementary Table 7), we observed 187 
total SNP-h2 estimates of 0.35 (SE=0.07), 0.43 (SE=0.05), and 0.39 (SE=0.07) respectively (Figure 5c). 188 
More importantly, this analysis suggested that a large proportion of genetic factors contributing to 189 
phenotypic variation in HC scores remains unchanged during the course of development, with genetic 190 
factors operating at the age of 1.5 years explaining 63.1% (SE=9%) and those at age 7 years 76.5% 191 
(SE=5%) of the genetic variance at age 15 years, respectively. Consistently, strong genetic correlations 192 
were identified among all scores during development (1.5-7 years, rg=0.89 (SE=0.07); 1.5-15 years, 193 
rg=0.79 (SE=0.09); 7-15 years, rg=0.87 (SE=0.04), in support of LD-score correlation analyses.  194 
 195 
 196 
Genetic correlation of complex phenotypes with HC   197 
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A systematic screen for genetic correlations between HC scores and 235 complex phenotypes 198 
using LD score correlation23, identified moderate to strong positive genetic correlations (rg≥0.3) with 199 
many anthropometric and cognitive / cognitive proxy traits. This includes HC scores during infancy, birth 200 
weight, birth length, height, extreme height, hip circumference, childhood obesity, waist circumference, 201 
intelligence scores and ICV (Supplementary Table 8, Figure 5d, Supplementary Data 9). Weaker positive 202 
genetic correlations (0<rg<0.3) were also present for years of schooling, obesity, body mass index, 203 
overweight and extreme height. 204 
The strongest cross-trait genetic correlation was identified between HC (Pediatric+adult) and ICV 205 
(rg=0.91(SE=0.16), p=1.6x10-8). However, there was little evidence that SNP-h2 estimates for HC are 206 
enriched for genes that are highly expressed in brain tissues or chromatin marks in neural and bone 207 
tissue/cell types, beyond chance (Supplementary Data 10) in the conducted HC meta-analyses. 208 
 209 
Combined genome-wide analysis of HC scores and ICV 210 
Given the prior expectation of similar genetic architectures between HC and ICV, supported 211 
through genetic correlation analyses, we meta-analyzed both phenotypes by combining HC summary 212 
statistics from pediatric and adult cohorts (N=18,881) with ICV summary statistics from the CHARGE 213 
and ENIGMA2 consortia12 (N=26,577, Figure 1b) using a Z-score weighted meta-analysis (Figure 6, 214 
Table 2, Supplementary Data 11, 12, 13). The strongest evidence for novel genetic association in this 215 
combined cranial dimension analysis was observed for the low-frequency marker rs78378222 216 
(MAF=0.02; p=7.9×10-11) at the 17p13.1 locus, a functional variant that is in LD with rs35850753, the 217 
strongest GWAS signal for HC (r2=0.56, p=3.6×10-9, Figure 3a and b, Supplementary Data 11). To study 218 
the independence of the two signals, we carried out conditional analyses. Adjusting rs35850753 for 219 
variation at rs78378222, the association with HC (Pediatric+adult) was strongly attenuated, but remains 220 
present at the nominal level (conditional β = 0.06 (SE=0.025), p=0.013). Reciprocally, the signal at 221 
rs78378222, conditional on rs35850753, was still detectable at the nominal level in the combined cranial 222 
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dimension analysis (conditional β = 0.051 (SE=0.017), p=0.0024), based on standardized regression 223 
estimates.  224 
In addition, we identified 8 independent genetic loci within the combined ICV and HC meta-225 
analysis that have not previously been reported for either HC or ICV (Supplementary Data 11). This 226 
includes evidence for association at rs9271147 (MAF=0.17; p=4.4×10-10) at 6p21.32 within the MHC 227 
region, which is in LD with rs9268812 (r2=0.41), a further signal from our HC (Pediatric+adult) meta-228 
analysis. We also observed increased statistical evidence for association at 9 known markers compared to 229 
the original studies for either HC, brain volume or ICV (Supplementary Data 12).  230 
 231 
 232 
Adding further genotype information from the HC follow-up cohort (N=973, Figure 1b), 233 
strengthened the evidence for association at both rs78378222 and rs35850753 (p=8.8×10-13 and p=4.9×10-234 
11 respectively, total N ≤ 43,529, Figure 3a and b, Supplementary Data 11), corresponding to a change in 235 
0.19 (SE=0.03) and 0.16 (SE=0.02) standard deviation (SD) units respectively. However, within 236 
neuroimaging samples only, support for association at rs78378222 was low in the combined CHARGE 237 
and ENIGMA2 samples12 (Table 2).  238 
Note that genetic effects with respect to a combined final cranial dimension cannot be translated 239 
into absolute units as HC scores and ICV relate to diametric versus volumetric properties respectively. 240 
 241 
 242 
Biological and phenotypic characterization of signals 243 
A detailed variant annotation of all novel signals for the combined ICV and HC meta-analysis, 244 
including overlapping signals from the HC meta-analysis alone, was carried out using the FUMA 245 
webtool25 (Supplementary Data 14-18) including variant annotation (Supplementary Data 16), mapped 246 
genes (Supplementary Data 17) and previously published studies (Supplementary Data 18). 247 
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The strongest cranio-dimensional signal, rs78378222, resides within the 3' untranslated region 248 
(UTR) of TP53 and the low-frequency allele leads to a change in the TP53 polyadenylation signal that 249 
results in impaired 3'-end processing for many TP53 mRNA. The strongest HC signal, rs35850753, 250 
resides within the 5'-UTR of the Δ133 TP53 isoforms and otherwise intronically (Figure 3b, 251 
Supplementary Data 16). Species comparison showed that variation at rs78378222 is highly conserved 252 
(GERP-score=5.28)26 and also predicted to be deleterious (CADD=17.97)27, while variation at 253 
rs35850753 is not (GERP-score=-2.8; CADD=1.04) (Figure 3b, Supplementary Data 16). According to a 254 
core 15-state chromatin model, variation at rs78378222, but not at rs35850753, is furthermore in LD 255 
(r2=0.8) with an enhancer in fetal brain (Figure 3b). Using the FUMA web tool25 and Brain xQTL28, we 256 
found no support for blood or brain cis eQTLs or meQTL in LD (r2>0.6) with either rs35850753 or 257 
rs78378222, when adjusted for the number of loci tested (Supplementary Data 19). The strongest 258 
evidence for cis eQTL at TP53 was found for eQTL in modest LD with rs35850753 (r2=0.22), explaining 259 
variation in gene level TP53 transcript in blood, with the rare T risk allele being associated with lower 260 
full-length transcript levels (False Discovery Rate q = 6x10-6, Supplementary Data 17). We also 261 
characterized the TP53 association signals for final HC and combined final ICV+HC phenotypically 262 
using a phenome-wide scan in the UK Biobank, as implemented in PHESANT29 (rs35850753: 263 
Supplementary Data 20). For rs35850753, standing height is increased by 0.012 cm (SE=0.002) and 264 
sitting height by 0.015 cm (SE=0.003) for each increase in minor effect allele. The log odds of having an 265 
inpatient primary diagnosis code for “Fracture of tooth” increase by 0.42 (SE=0.078) and the log odds of 266 
a participant answering "yes" to "ever had hysterectomy" by 0.06 (SE=0.011) per effect allele. For each 267 
increase in minor effect allele of rs78378222, standing height is increased by 0.015 cm (SE=0.002) and 268 
sitting height by 0.019 cm (SE=0.003). The log odds of a participant answering "yes" to "ever had 269 
hysterectomy" was 0.065 (SE=0.011) per effect allele. Sensitivity analysis adjusting, in addition, for 10 270 
principal components did not change the nature of these findings (Supplementary Data 20). 271 
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Furthermore, we identified variants in LD with the two cranial dimension signals at 1q44 and at 272 
2p25.1 respectively that are predicted to be deleterious. rs12408455 (r2 with rs2168812 = 0.99) is an 273 
intronic SNP within AKT3 (CADD = 17.87) and rs112040334 (r2 with rs4513262 = 0.91) an intronic 11-274 
bp insertion/deletion within KLF11 (CADD = 17.22, Supplementary Data 16). Both variants are in LD (r2 275 
> 0.6) with eQTL in blood (Supplementary Data 17), with the effect allele at both variants being 276 
associated with increasing transcript levels of AKT3 and KLF11 respectively. The variant with the highest 277 
CADD score identified in the combined ICV and HC meta-analysis is rs41288837. This low-frequency 278 
missense variant at 2p11.2 within TCF7L1 is predicted to belong to the 0.5% most deleterious 279 
substitutions in the human genome (MAF = 0.03, CADD = 24.30, Table 2, Supplementary Data 16). We 280 
observed no evidence for associated eQTL in blood or brain for this variant (Supplementary Data 17).  281 
Notably, many genes containing SNPs in LD (r2 > 0.6) with lead variants from the combined ICV 282 
and HC meta-analysis show mapped chromatin interactions within mesenchymal and human embryonic 283 
stem cells and mesoendoderm (Supplementary Data 17), including TP53. 284 
 285 
 286 
  287 
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Discussion 288 
Investigating up to 46,000 individuals of European descent, this study identifies and replicates 289 
evidence for genetic association between a novel region on chromosome 17p13.1 and both final HC and 290 
ICV+HC, implicating low-frequency variants of large effect within TP53. We furthermore demonstrate 291 
that the genetic architecture of HC is developmentally stable and genetically correlated with ICV. This is 292 
supported by the identification of 8 further common and rare independent loci that are associated with 293 
cranial dimension as a combined HC and ICV phenotype, illustrating the allele frequency spectrum of the 294 
underlying genetic architecture.  295 
For final HC, the strongest evidence for association at 17p13.1 is observed with rs35850753, 296 
while final cranial dimension is most strongly associated with rs78378222. Both rs35850753 and 297 
rs78378222 are low-frequency variants, in partial linkage disequilibrium, and their effect sizes are 298 
substantially larger than any previously reported GWAS signals for either HC or ICV alone, reaching 299 
nearly a fifth and quarter of a SD unit change in final cranial dimension and final HC per rare effect allele 300 
respectively. For HC, this translates into an increase of approximately 0.5 cm in HC between carriers and 301 
non-carriers of rare alleles at the age of 10 years. Based on longitudinal analyses, it is most likely that 302 
genetic effects of rs35850753 on final HC start to emerge during mid-childhood, while we have no 303 
comparable longitudinal data source available to evaluate trajectory effects on cranial dimension. 304 
TP53 encodes the p53 protein, a transcription factor that binds directly and specifically as a 305 
tetramer to DNA in a tissue- and cell-specific manner and has a range of anti-proliferative functions, 306 
lending it the nickname guardian of the genome. The activation of p53 in response to cellular stress 307 
promotes cell cycle arrest, DNA repair and apoptosis30. TP53 mutations are present in approximately 30% 308 
of tumor samples making it one of the most studied genomic loci with over 27,000 somatic and 550 309 
germline mutations described to date (source - IARC TP53 database31). The low-frequency allele at 310 
rs78378222 leads to a change in the TP53 polyadenylation signal that results in impaired 3'-end 311 
processing and termination of many TP53 mRNA isoforms32, including full length TP53 isoforms, 312 
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although rs78378222 is also in LD with an enhancer region in fetal brain. In contrast, rs35850753 resides 313 
in the 5΄ UTR of TP53 Δ133 isoforms that are transcribed by an alternative promoter. This leads to the 314 
expression of an N-terminally truncated p53 protein, initiated at codon 133, lacking the trans activation 315 
domain33. TP53 Δ133 isoforms are known to directly and indirectly modulate p53 activity and 316 
differentially regulate cell proliferation, replicative cellular senescence, cell cycle arrest and apoptosis in 317 
response to stress such as DNA damage, including the inhibition of tumor suppressive functions of full-318 
length p53. This mechanism is consistent with the observed link between the rs35850753 low-frequency 319 
T allele and lower full length TP53 transcript level. Thus, rare effect alleles at both rs78378222 and 320 
rs35850753 could potentially, via different biological mechanisms, be linked to impaired p53 activity and 321 
thus heightened proliferative potential and less apoptosis of normal human cells, consistent with larger 322 
HC scores and a larger cranial dimension.  323 
It is noteworthy that rs78378222 has been previously associated to risk of cancers including 324 
tumors of the nervous system such as glioma34, a malignant tumor of glial tissue, possibly including 325 
neural stem cells, glial progenitors and astrocytes as cells of origin35, but also prostate cancer and 326 
colorectal adenoma32. Both, rs35850753 and rs78378222 have also been robustly associated with 327 
neuroblastoma36, a sympaticoadrenal lineage neural crest-derived tumor. Evidence for neurological 328 
phenotypic consequences of TP53 variation has recently been strengthened by the discovery of TP53 as a 329 
risk locus for general cognitive function using a gene-based approach37. TP53 knockout mouse embryos 330 
show furthermore broad cranial defects involving skeletal, neural and muscle tissues38. Similarly, mouse 331 
models for Treacher Collins syndrome (a disorder of cranial morphology which arises during early 332 
embryological development as a result of defects in the formation and proliferation of neural crest cells) 333 
could be rescued by inhibition of p53 during embryological patterning39. In particular, there is support 334 
from animal and tissue models for a role of p53 in neural crest cell (NCC) development38 with NCCs 335 
supplementing head mesenchyme during fetal development11,40. NCCs also contribute to the development 336 
of a thick 3-membrane layer called the meninges, that cover the telencephalon11,40 and directly locate 337 
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underneath the skull. In particular, Pia mater, the innermost layer of the meninges, adheres closely to sulci 338 
and fissures of the cortex. During postnatal brain growth, including extensive increases in myelinated 339 
white matter41, the calvarial bones are drawn outward, partially due to the expanding meninges, triggering 340 
the production of membranous skull bone40. Moreover, meninges have been thought to play a key role in 341 
the coordinated integration of signaling pathways regulating both neural and skeletal cranial growth11. It 342 
is possible to speculate that p53 is part of these joint regulatory mechanisms, for example, via Wnt 343 
signaling regulation42. However, beneficial effects of rs35850753 and rs78378222 on growth patterning 344 
leading to an increased HC and cranial dimension might be counterbalanced by adverse outcomes such as 345 
glioblastoma, keeping both variants at a lower frequency.  346 
Combined analysis of HC and ICV, as related measures of final cranial dimension, also identified 347 
association at 8 further loci, in addition to variation at 17p13.1 and loci previously reported for either 348 
infant HC and/or adult ICV. This includes the low-frequency variant rs41288837, predicted to belong to 349 
the 0.5% most deleterious substitutions in the human genome. The variant exerts moderately large effects 350 
that correspond to an approximately 10% decrease in SD units of final cranial dimension per rare T allele. 351 
rs41288837 is a missense variant in TCF7L1 at 2p11.2, a locus encoding a transcription factor mediating 352 
Wnt signaling pathways that are known to play an important role in vertebrate neural development43. The 353 
effects of this variant were consistent for both HC and ICV, although each of the individual trait analyses 354 
was too underpowered to detect association at this variant at a genome-wide level. An additional low-355 
frequency variant in this study, rs183336048 at 4q28.1, was identified as associated with pediatric HC 356 
only, but could not be replicated due to a lack of comparable age-matched follow-up cohorts. 357 
rs183336048 lies 5' to INTU which encodes inturned planar cell polarity protein, a polarity effector 'with 358 
roles in neural tube patterning and cilliation44. Common variants identified in the ICV+HC combined 359 
meta-analysis also include intronic variation in AKT3 (rs2168812) and CCND2 (rs3217870), which are 360 
related through the phosphatidylinositol 3-kinase (PI3K-AKT) pathway45. Disruption of PI3K-AKT 361 
pathway components causes megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome and a 362 
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spectrum of related megalencephaly syndromes45,46. This supports previous in silico pathway analysis, 363 
which nominated PI3K-AKT, an intracellular signaling pathway controlling the cell cycle, as candidate 364 
pathway for intracranial volume12. Both, rs2168812 and rs3217870, have also been associated with cancer 365 
risk, similarly to the two TP53 variants, with the AKT3 variant rs12076373 (LD-r2 with rs2168812: 0.70) 366 
being related to risk for non-glioblastoma brain tumors34 and the CCND2 variant rs3217901 (LD-r2 with 367 
rs3217870: 0.63) being related to colorectal cancer (Supplementary Data 18). Notably, AKT3 signaling is 368 
an essential intracellular pathway controlling neural crest development47, while tissue-specific chromatin 369 
interactions in mesenchymal stem cells have been reported for several novel loci (Supplementary Data 370 
17), supporting a role of neural crest related processes in shaping final cranial dimension.  371 
 Genetic correlation analyses provided strong evidence for shared genetic determinants between 372 
HC and both anthropometric (birth weight, height, waist and hip circumference) and cognitive traits, as 373 
well as ICV. Genetic correlations with waist circumference and hip circumference recapitulate observed 374 
correlations between the size of the maternal pelvis and the size of the neonatal cranium48, possibly 375 
induced because bipedal locomotion limits pelvic size. This is important as a mismatch between the 376 
maternal pelvis and the fetal head49, i.e. a cephalopelvic disproportion (CPD, also known as fetopelvic 377 
disproportion), can put the lives of both mother and fetus at risk, if left untreated. Mathematical models 378 
show that evolutionary forces such as a weak directional selection for a large neonate and/or a weak 379 
selection for a narrow pelvis can account for the considerable incidence of CPD in humans50, and predict 380 
a further rise in CPD incidence due to the frequent use of Caesarian sections during recent years.  381 
We also confirmed previously-reported genetic links between educational attainment and infant 382 
HC51, and identified additional evidence for genetic correlation between HC and intelligence, especially 383 
pediatric HC. With strongly shared genetic liability (i.e. a genetic correlation coefficient near one), we 384 
considered HC and ICV to be related proxy measures of an underlying phenotype, which we termed final 385 
cranial dimension. This also suggests that estimated skeletal volume, a combination of HC, cranial height 386 
and cranial length52, might represent a more accurate, easily accessible and inexpensive measure to 387 
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enhance power for future genetic analysis using a multi-trait approach53 in combination with ICV, 388 
exploiting similar volumetric properties. 389 
Multivariate analyses of genetic variance showed that genetic factors contributing to variation in 390 
HC during infancy explain the majority of genetic variance during later life, although novel genetic 391 
influences arise both during mid-childhood and adolescence. This is further reflected in strong GSEM-392 
based genetic correlations across childhood and adolescence, and strong LDSC-based genetic correlations 393 
between infant and adult HC. The estimated LDSC-heritability of HC in adult samples was lower than in 394 
pediatric samples, with only marginally overlapping 95% confidence intervals, implying that phenotypic 395 
variation in final HC is less well accounted for by genetic influences than in childhood, probably as 396 
skeletal growth processes have ceased.  397 
The discovery that low-frequency variation, especially near TP53, is associated with HC 398 
demonstrates the scientific value of testing for variation in the lower allele frequency spectrum and the 399 
utility of comprehensive imputation templates. Low-frequency variants identified in this study had larger 400 
effects than common variants (Supplementary Figures 7 and 8), in keeping with findings from a range of 401 
complex phenotypes including anthropometric traits17,54,55. Nevertheless, despite having sufficient power 402 
to detect low-frequency variation explaining as little as 0.11% of the variance in HC, this study was 403 
underpowered for rare variant analysis (Supplementary Note 4), underlining the need for even larger 404 
research efforts. Collectively, our findings provide insight into the genetic architecture of cranial 405 
development and contribute to an improved understanding of its dynamic nature throughout human 406 
growth and development. 407 
 408 
  409 
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Methods 410 
Study population  411 
For the discovery analysis, we adopted a two-stage developmental design including cohorts with 412 
HC scores during childhood (Pediatric HC, mean age 6 to 9 years of age, N=10,600), during adulthood 413 
(Adult HC, mean age 44 to 61 years of age, N=8,281) and a combination thereof (N=18,881) including 414 
individuals of European descent from 11 population-based cohorts (Supplementary Table 1 and 2, Figure 415 
1). Cohorts include The Avon Longitudinal Study of Parents and Children (ALSPAC), the Generation R 416 
Study (GenR), the Western Australia Pregnancy Cohort Study (RAINE), the Copenhagen Prospective 417 
Study on Asthma in Children (COPSAC2000 and COPSAC2010), the Infancia y Medio Ambiente cohort 418 
(INMA), the Hellenic Isolated Cohorts HELIC-Pomak and HELIC-MANOLIS, the Orkney Complex 419 
Disease Study (ORCADES), the Croatian Biobank Korčula (CROATIA-KORCULA), and the Viking 420 
Health Study-Shetland (VIKING). Within ALSPAC analysis was performed separately in individuals 421 
with whole-genome sequence data (ALSPAC WGS) and chip-based genotyping (ALSPAC GWA). For 422 
follow-up, we studied 973 individuals from the Croatian Biobank, Split (CROATIA-SPLIT) 423 
(Supplementary Table 2). Institutional and/or local ethics committee approval was obtained for each 424 
study. Written informed consent was received from every participant within each cohort, and this study 425 
has complied with all ethical regulations. An overview of each cohort can be found in Supplementary 426 
Tables 1 and 2 with more detailed information in the Supplementary Note 1. 427 
 428 
Genotyping 429 
Within ALSPAC, we obtained low read depth (average 7x) whole-genome sequencing data 430 
(ALSPAC WGS)55. Chip based genotyping was performed on various commercial genotyping platforms, 431 
depending on the cohort (Supplementary Table 1). Prior to the imputation, all cohorts had similar quality 432 
control; variants were excluded because of high levels of missingness (SNP call rate <98%), strong 433 
departures from Hardy-Weinberg equilibrium (p<10-6), or low MAF (<1%). Individuals were removed if 434 
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there were sex discordance, high heterozygosity, low call rate (<97.5%) or duplicates. For imputation, the 435 
reference panel was either joint UK10K/1000 Genomes55 or the Haplotype Reference Consortium15. 436 
Additional details can be found in Supplementary Table 1 and Supplementary Note 1. 437 
In addition to study-specific quality control measures, central quality control was performed 438 
using the EasyQC R package56. First, variants were filtered for imputation quality score (imputed studies 439 
only, INFO>0.6), minor allele count (MAC; ALSPAC WGS MAC>4, all imputed studies MAC>10) and 440 
a minimum MAF of 0.0025. SNPs with MAF discrepancies (>0.30) compared to the HRC panel were 441 
also excluded. Marker names were harmonized and reported effect and non-effect alleles were compared 442 
against reference data (Build 37). Variants with missing or mismatched alleles were dropped, in addition 443 
all insertion/deletions (INDELs), duplicate SNPs and multiallelic SNPs were excluded. The reported 444 
effect allele frequency for each study was plotted against the frequency in the HRC reference data to 445 
identify possible strand alignment issues (Supplementary Figure 1, 3). The final number of variants 446 
passing all quality control tests and the per-study genomic inflation factor (λ) are reported in 447 
Supplementary Table 1 and 2.  448 
 449 
Phenotype preparation 450 
Pertinent to this study, HC measures in all individual cohorts were transformed into Z-scores 451 
using a unified protocol. After the removal of outliers (+/- 4 SD within each sample), HC was adjusted for 452 
age within males and females separately. Residuals for each sex were subsequently transformed into Z-453 
scores and eventually combined (thus removing inherent sex-specific effects). Note that the phenotype 454 
transformation within ALSPAC was jointly carried out for both sequenced and genome-wide imputed 455 
samples. 456 
 457 
 458 
Genetic-relationship structural equation modelling 459 
20 
 
Developmental changes in the genetic architecture of HC scores between the ages of 1.5 and 15 460 
years were modelled using genetic-relationship structural equation modelling (GSEM, R gsem library, 461 
v0.1.2)24. This multivariate analysis of genetic variance combines whole-genome genotyping information 462 
with structural equation modelling techniques using a full information maximum likelihood approach24. 463 
Changes in genetic variance composition were assessed with longitudinal HC scores in ALSPAC 464 
participants (7924 individuals with up to three measures; 1.5 years, N=3,945; 7 years N=5,819; 15 years, 465 
N=3,406). HC scores were Z-standardised at each age, as described above. Genetic-relationship matrices 466 
were constructed based on directly genotyped variants in unrelated individuals, using GCTA software57, 467 
and the phenotypic variance dissected into genetic and residual influences using a full Cholesky 468 
decomposition model24.  469 
 470 
Multiple testing correction 471 
Using Matrix Spectral Decomposition (matSpD)58, we estimated that we analyzed 1.52 effective 472 
independent phenotypes within this study (Pediatric, Adult and Pediatric+adult HC scores and ICV12 473 
scores) according to LDSC-based genetic correlations22.  474 
 475 
Single variant association analysis 476 
Single variant genome-wide association analysis, assuming an additive genetic model, was 477 
carried out independently within each cohort using standard software (Supplementary Table 1, 478 
Supplementary Note 1). Residualized HC scores (Z-scores) were regressed on genotype dosage using a 479 
linear regression framework. For cohorts with unrelated subjects (Supplementary Table 1) association 480 
analysis was carried out using SNPTEST v2.5.0 (-method expected, -frequentist)59. Note that HC scores 481 
in GenR were, in addition, adjusted for four principal components. Cohorts with related participants 482 
(HELIC cohorts) utilized a linear mixed model to control for family and cryptic relatedness, implemented 483 
in GEMMA60.  484 
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Individual cohort level summary statistics for HC were combined genome-wide with standard 485 
error-weighted fixed effects meta-analysis, allowing for the existence of age-specific effects through an 486 
age-stratified design (Figure 1a). We restricted each HC meta-analysis (Pediatric, Adult, Pediatric+adult) 487 
to variants with a minimum sample size of N>5000. Genomic control correction was applied at the 488 
individual cohort level and heterogeneity between effects estimates was quantified using the I-squared 489 
statistic as implemented in METAL61. Accounting for the effective number of independent phenotypes 490 
studied, the threshold for genome-wide significance was fixed at 3.3x10-8 and the threshold for suggestive 491 
evidence at 6.6x10-6.  492 
We contacted all studies (known to us) with a) HC information available in later childhood or 493 
adult samples b) participants of European ancestry and c) genotype data. Studies with whole-genome 494 
sequencing or densely imputed genotype data (HRC or UK10K/1KG combined templates) were included 495 
in the HC meta-analysis, while studies with imputation to other templates were reserved for follow-up. 496 
Following this strategy, the majority of studies were included in meta-analysis, with follow-up in a single 497 
study. 498 
 499 
Identification of known variants and conditional analysis 500 
Known GWAS signals (p ≤ 5x10-8) were identified from previous studies on HC in infancy13, 501 
ICV12,62-64 and brain volume65 using either published or publicly available data (Supplementary Table 4). 502 
Conditional analysis was performed with GCTA software using summary statistics from HC (Pediatric) 503 
and HC (Pediatric+adult) meta-analyses (Supplementary Figure 4). In addition, we carried out an LD 504 
clustering of independent signals from the HC (Pediatric+adult) meta-analysis with respect to all known 505 
loci. Briefly, LD clustering is an iterative process that starts with the most significant SNP, which is 506 
clumped with variants that have pairwise LD of r2 ≥ 0.2 within 500 kb using PLINK v1.90b3w, and all 507 
variants in LD are removed. Then, the same clumping procedure is repeated for the next top SNP and the 508 
iteration continues until there are no more top variants with p<10-4. For details, see Supplementary Note 509 
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2. For sensitivity analysis, we repeated the LD clustering with known loci for height as identified through 510 
the GIANT consortium (697 known independent height GWAS signals19, r2=0.2 , +/-500 kb). 511 
 512 
Combined meta-analysis of HC and ICV  513 
We carried out a weighted Z-score meta-analysis of the combined HC (Pediatric+adult) meta-514 
analysis and the largest publicly available genome-wide statistics on intracranial volume (ICV; 515 
N=26,577) based on data from Cohorts for Heart and Aging Research in Genomic Epidemiology 516 
(CHARGE) and the Enhancing NeuroImaging Genetics through Meta-Analysis (ENIGMA) consortium12. 517 
A weighted Z-score meta-analysis was carried out using METAL 61 using standardized regression 518 
coefficients and 12,124,458 imputed or genotyped variants, assuming a genome-wide threshold of 519 
significance at p ≤ 3.3x10-8. 520 
We used the Z-scores (Z) from the METAL output to calculate the standardized regression 521 
coefficient (β) for each SNP and trait66 522 
 523 
ߚఫ෡ ≈ ௝ܼ ఙ೤ෞඥேೕ×ଶ(ଵିா஺ிೕ)ா஺ிೕ      (1) 524 
 525 
where SNP j has an effect allele frequency (EAFj) and ߪ௬ෞ is standard deviation of the phenotype, which is 526 
assumed to equal one for standardised traits. The standard error (SE) is calculated as 527 
௝ܼ = ఉണ
෢
ௌா(ఉണ෢)       (2) 528 
 529 
To disentangle lead signals observed in both, the HC (Pediatric+adult) and the combined ICV+HC 530 
(Pediatric+adult) meta-analysis, variants were conditioned on each other using GCTA software and 531 
summary statistics. 532 
 533 
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Gene based analysis 534 
Gene based tests for association were performed using MAGMA20, which calculates gene-based 535 
test statistics from SNP-based test statistics, position-based gene annotations and a linkage disequilibrium 536 
reference panel of UK10K haplotypes using an adaptive permutation procedure. SNP-based test statistics 537 
were annotated using mapping files with a 50 kb symmetrical window around genes. For gene definition, 538 
we used all 19,151 protein-coding gene annotations from NCBI 37.3 and corrected for the number of 539 
genes and effective phenotypes tested, using an adjusted Bonferroni-threshold of 1.7x10-6. 540 
 541 
S-PrediXcan  542 
We used the S-PrediXcan method21 as a summary-statistic based implementation of PrediXcan to 543 
test for association between tissue-specific imputed gene expression levels and HC, implemented in the 544 
MetaXcan standalone software (v0.3.5). This approach first predicts the transcriptome level using 545 
publicly available transcriptome datasets. Then, it infers the association between gene and phenotype of 546 
interest, by using the SNP-based prediction of gene expression as weights (predicted from the previous 547 
step) and combines it with evidence for SNP association based on phenotype-specific GWAS summary 548 
statistics. We predicted gene expression levels for cerebellum (4778 genes; GTEx v6p; Supplementary 549 
Note 3), cortex (3177 genes; GTEx v6p; Supplementary Note 3) and whole blood (6669 genes; DGN; 550 
Supplementary Note 3) using an adjusted Bonferroni threshold of p< 2.3x10-6 across all tissues tested. 551 
 552 
Estimation of heritability and genetic correlation 553 
Linkage-disequilibrium score regression (LDSC)22 was carried out to estimate the joint 554 
contribution of genetic variants as tagged by common variants (SNP-h2) to phenotypic variation in HC. 555 
The method is based on GWAS summary statistics and exploits LD patterns in the genome and can 556 
distinguish confounding from polygenic influences22. To estimate LDSC-h2, genome-wide χ2-statistics are 557 
regressed on the extent of genetic variation tagged by each SNP (LD-score). The intercept of this 558 
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regression minus one estimates the contribution of confounding bias to inflation in the mean χ2-statistic. 559 
LD score regression was performed with LDSC software (v1.0.0) and based on the set of well-imputed 560 
HapMap3 SNPs (~1,145,000 SNPs with minor allele frequency (MAF) > 5% and high imputation quality 561 
such as an INFO score of 0.9 or higher) and a European reference panel of LD-scores. LD-score 562 
correlation analysis can be used to estimate the genetic correlation (rg ) between distinct samples by 563 
regressing the product of test statistics against the same LD-score23. Bivariate LD score correlation was 564 
performed with the LDHub platform67 v1.9.0 (Supplementary Note 5). We assessed the genetic 565 
correlation between HC scores and a series of 235 phenotypes (excluding UK Biobank) comprising 566 
anthropometric, cognitive, structural neuroimaging and other traits as described in Zheng et al.67, with an 567 
adjusted Bonferroni threshold of p<1.4x10-4.  568 
 569 
Stratified LD score regression  570 
Stratified LD score regression68 is a method for partitioning heritability from GWAS summary 571 
statistics with respect to genes that are expressed in specific tissue/cell types. We applied this method to 572 
HC summary statistics to evaluate whether the heritability of HC is enriched for genes that are highly 573 
expressed in brain tissues. GTEx v6p (Supplementary Note 3) provided gene expression data from 13 574 
brain tissue/cell types. Each of these tissue annotations was added to the baseline model and enrichment 575 
was calculated with respect to 53 functional categories. This is for each functional category the proportion 576 
of SNP-h2 divided by the proportion of SNPs in that category. We performed stratified LD score 577 
regression with independent data from the Roadmap Epigenomics consortium and ENCODE project 578 
(Supplementary Note 3), where we restricted the analysis to 55 chromatin marks identified in neural and 579 
bone tissue/cell types. Similar to the deriving enrichment in gene expression, each annotation was added 580 
to the baseline model. Chromatin analysis includes the union and the average of cell-type specific 581 
annotations within each mark. The joint gene expression and chromatin enrichment analysis, we applied a 582 
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multiple testing of p<4.8x10-4 accounting for 68 neural and bone tissues/cell types tested (data from 583 
GTEx v6p, ENCODE and Roadmap; Supplementary Note 3). 584 
 585 
Functional annotation of novel signals 586 
Functional consequences of novel variants were explored using two web-based tools: Brain 587 
xQTL28 and FUMA (v1.3.1)25. The threshold for multiple testing for eQTL was adjusted according to the 588 
number of genes near the studied novel signals and their proxy SNPs (r2=0.2 and ±500kb). For Brain 589 
xQTL, we corrected for multiple testing based on a threshold of p<7.4x10-4 to account for 68 genes tested. 590 
For FUMA eQTL analysis, a multiple testing threshold of p<7.6x10-4 was applied to adjust for 42 genes 591 
and, 24 blood and brain tissues/cell types (Supplementary Note 3).  592 
 593 
UK Biobank phenome scan  594 
To characterize the phenotypic spectrum of identified HC signals, we conducted a phenome scan 595 
on 2,143 phenotypes in the UK Biobank cohort69, using PHESANT29 software (v0.13). Analyses were 596 
restricted to participants of UK ancestry (UK Biobank specified variable). One from each pair of related 597 
individuals, individuals with high missingness, heterozygosity, gender mismatch and putative 598 
aneuploidies were excluded. Genotype dosage at lead single variants identified in GWAS was converted 599 
into best-guess genotypes using PLINK v1.90b3w. Linear, ordinal logistic, multinomial logistic and 600 
logistic regressions were fitted to test the association between genotype and continuous, ordered 601 
categorical, unordered categorical and binary outcomes respectively. Analyses were adjusted for age, sex 602 
and genotyping chip, and, for sensitivity analysis, 10 principal components. A conservative Bonferroni 603 
threshold was applied accounting for a total of 11,056 tests performed and 2 genotypes tested (p<2.26×10-604 
6).  605 
 606 
HC growth curve modelling 607 
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Trajectories of untransformed HC (cm) spanning birth to 15 years were modelled in 6,225 608 
ALSPAC participants with up to 13 repeat measures (17,269 observations) using a mixed effect SITAR 609 
model18 (R sitar library v1.0.11). SITAR comprises a shape invariant mixed model with a single fitted 610 
curve, where individual curves are matched to the mean curve by modelling differences in mean HC, 611 
differences in timing of the pubertal growth spurt and differences in growth velocity18. Individuals with 612 
large measurement errors, i.e. with HC scores at younger ages exceeding scores at later ages (by more 613 
than 0.5 SD of the grand mean) as well as outliers (with residuals outside the 99.9% confidence interval) 614 
were excluded. The best fitting model was identified using likelihood ratio tests and the Bayesian 615 
Information Criterion and included four fixed effects for splines, a fixed effect for differences in mean 616 
HC and a fixed effect for sex, in addition to two random effects for differences in mean HC and growth 617 
velocity. Stratified models were fitted for carriers and non-carriers of increaser-alleles at candidate loci. 618 
To examine the relationship between genotype dosage and differences in HC and growth velocity, these 619 
random effects were regressed on genotype dosage using a linear model.  620 
 621 
Data availability 622 
Genome-wide summary statistics  and further analyses in this work  that support the findings of 623 
this study have been deposited at "The Language Archive", a public data archive hosted by the Max 624 
Planck Institute for Psycholinguistics. Data are accessible with a persistent identifier 625 
(https://hdl.handle.net/1839/ff12326d-9688-4a46-bc2a-b50cbbd2b20c). The content can also be found 626 
through the Data Archiving and Networked Services database, the Dutch national organization for 627 
sustained access to digital research data. All Supplementary Data files can be found under the following 628 
links: 629 
Supplementary Data 1 [https://hdl.handle.net/1839/d2168cc5-402b-47f2-93b1-a62e087801e0] 630 
Supplementary Data 2 [https://hdl.handle.net/1839/f84fa813-d9c1-4f06-b53c-f8d298173d89] 631 
Supplementary Data 3 [https://hdl.handle.net/1839/c832af6a-f0d0-4f88-b6e5-17d18d849ae3] 632 
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Supplementary Data 4 [https://hdl.handle.net/1839/1e6037e3-88de-48bb-921e-06c1496b08d4] 633 
Supplementary Data 5 [https://hdl.handle.net/1839/3407cdb9-31ee-493b-b2b6-fb33469295d0] 634 
Supplementary Data 6 [https://hdl.handle.net/1839/0bb0767d-71f6-4d97-8046-bc7f0339f424] 635 
Supplementary Data 7 [https://hdl.handle.net/1839/627bee91-39cc-42d9-b6ac-d446d7130f2a] 636 
Supplementary Data 8 [https://hdl.handle.net/1839/7e8de22b-a232-4e3a-8ffe-8ae3541edc66] 637 
Supplementary Data 9 [https://hdl.handle.net/1839/c6ce553c-db42-46dc-b262-20ba705f0c5b] 638 
Supplementary Data 10 [https://hdl.handle.net/1839/dd8ce2ba-5661-4f57-8274-1aa028f0b72f] 639 
Supplementary Data 11 [https://hdl.handle.net/1839/69006cf2-cc8c-4e11-8341-009b8fc0cfb6] 640 
Supplementary Data 12 [https://hdl.handle.net/1839/f7ac7c11-404d-4756-8de1-8832c1a1cba7] 641 
Supplementary Data 13 [https://hdl.handle.net/1839/16b9bf3c-ddeb-41fa-898e-016fda8d62e1] 642 
Supplementary Data 14 [https://hdl.handle.net/1839/c2043ff0-3059-42e4-be50-ba208f1df14e] 643 
Supplementary Data 15 [https://hdl.handle.net/1839/b26a6813-cdb4-4496-bbc9-d1b177dd1691] 644 
Supplementary Data 16 [https://hdl.handle.net/1839/efc9a201-7729-43e8-ad16-f93e5dc56a6f] 645 
Supplementary Data 17 [https://hdl.handle.net/1839/940e469d-2f08-49b6-908b-24e5565f294b] 646 
Supplementary Data 18 [https://hdl.handle.net/1839/e2796a3b-1061-4a5c-abe7-256e97d5b0c8] 647 
Supplementary Data 19 [https://hdl.handle.net/1839/52f85e2e-f567-4e7a-9de2-aef7331c4127] 648 
Supplementary Data 20 [https://hdl.handle.net/1839/42e9a654-9ff7-4fd5-a10a-38a71455d4b6] 649 
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Figure legends 1031 
 1032 
Figure 1. Study design. (a) Head circumference meta-analysis design using a fixed-effect meta-analysis 1033 
including different developmental stages. (b) Combined head circumference and intracranial volume 1034 
meta-analysis design using a Z-weighted meta-analysis. ICV - intracranial volume. WGS - Whole 1035 
Genome Sequencing; UK10K/1KG - Joint UK10K/1000 Genomes imputation template; 1KG - 1000 1036 
Genomes imputation template; HRC- The Haplotype Reference Consortium r1. * Due to sample dropout 1037 
only N ≤ 43,529 were available 1038 
 1039 
  1040 
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Figure 2: Genome-wide association with final head circumference (HC). (a) HC(Pediatric): N=8,281, 1041 
(b) HC(Adult): N=10,600 and (c) HC(Pediatric+adult): N=18,881 inverse-variance weighted meta-1042 
analyses. The dashed line represents the threshold for nominal genome-wide (p<5.0x10-8) significance. 1043 
Accounting for multiple testing, the adjusted level of genome-wide significance is p<3.3x10-8. Known 1044 
variants for intracranial volume, brain volume and head circumference are shown in blue. Novel signals 1045 
passing a nominal genome-wide association threshold (p<5x10-8) are shown with their lead SNP in red. 1046 
Replicated signals are labelled with a red cross. The genomic position is shown according to NCBI Build 1047 
37.  1048 
 1049 
  1050 
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Figure 3. Regional association plot at 17p13.1 associated with final head circumference (HC) and 1051 
final cranial dimension. (a) Depicts a 800 Mb window and (b) a zoomed view of genetic association 1052 
signals and functional annotations near TP53. Within each plot, in the first panel SNPs are plotted with 1053 
their -log10 p-value as a function of the genomic position (b37). This panel shows the statistical evidence 1054 
for association based on HC (Pediatric+adult) and combined ICV+ HC (Pediatric+adult) meta-analyses, 1055 
including HC follow-up studies. SNPs are colored according to their correlation with the HC lead signal 1056 
(rs35850753, pairwise LD-r2-values). The second panel represents the gene region (ENSEMBL 1057 
GRCh37). The third panel in (b) presents the Genomic Evolutionary Rate Profiling (GERP++) score of 1058 
mammalian alignments. The last four panels in (b) show 4 of 15 core chromatin states, present in the 1059 
zoomed view, from the Roadmap Epigenomics Consortium including Embryonic Stem Cells (ESC), 1060 
hESC Derived CD56+ Ectoderm Cultured Cells, Fetal Brain (Male) and Brain Dorsolateral Prefrontal 1061 
Cortex respectively (see legend for color coding). 1062 
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Figure 4. Stratified head circumference growth model trajectories for rs35850753 carriers (T allele) 1065 
versus non-carriers (C-allele). The growth model was based on untransformed head circumference (cm) 1066 
scores spanning birth to 15 years observed in 6,225 ALSPAC participants with up to 13 repeat measures 1067 
(17,269 observations) using a mixed effect SuperImposition by Translation And Rotation (SITAR) 1068 
model. 1069 
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Figure 5: Genetic architecture of head circumference (HC). (a) Linkage-disequilibrium score SNP-1072 
heritability (LDSC-h2) for HC (Pediatric), HC (Adult) and HC (Pediatric+adult) meta-analyses. (b) 1073 
Genetic-relationship matrix structural equation modelling (GSEM) of head circumference during 1074 
development: Path diagram of the full Cholesky decomposition model using longitudinal head 1075 
circumference measures from ALSPAC (1.5 years (N =3,945), 7 years (N=5,819), and 15 years 1076 
(N=3,406)). Phenotypic variance (P1, P2, P3) was dissected into genetic (A1, A2 and A3) and residual 1077 
(E1, E2 and E3) factors. Observed measures are represented by squares and latent factors by circles. 1078 
Single headed arrows  define relationships between variables. The variance of latent variables is 1079 
constrained to unit variance. (c) Standardized genetic and residual variance components for head 1080 
circumference during development. Variance components were estimated using the GSEM model as 1081 
shown in b. (d) Linkage-disequilibrium score correlation (LDSC-rg) for HC(Pediatric), HC(Adult) and 1082 
HC(Pediatric+adult) and 235 phenotypes: 17 genetic correlation estimates passing a Bonferroni threshold 1083 
(p<0.00014) are shown with their standard errors.  *** p<10-8; **p<10-5; *p<0.00014 1084 
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Figure 6: Genome-wide association analysis of final cranial dimension  1089 
A genome-wide weighted Z-score meta-analysis of combined head circumference (HC) and intracranial 1090 
volume (ICV) was carried out (ICV+HC (Pediatric+adult): N= 45,458). The dashed line represents the 1091 
threshold for nominal genome-wide (p<5.0x10-8) significance. Accounting for multiple testing, the 1092 
adjusted level of genome-wide significance is p<3.3x10-8. Known variants for ICV, brain volume and HC 1093 
are shown in blue. Novel signals passing a nominal genome-wide association threshold (p<5 x10-8) are 1094 
shown with their lead SNP in green (Table 2, Table S15). HC (Pediatric + adult) signals identified in this 1095 
study are shown in red. The genomic position is shown according to NCBI Build 37.  1096 
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Tables 1099 
 1100 
Table 1: Novel loci for final head circumference 1101 
Variant Chr:Pos (b37) EA: EAF 
Discovery Follow-up Discovery + follow-up NTotal 
β 
(SE) p phet 
β 
(SE) p 
β 
(SE) p  
HC(Pediatric) 
rs183336048 4:12830274 T: 0.02 0.31 (0.06) 3.0×10
-8 0.62 - - - - 10,303 
HC(Pediatric+adult) 
rs9268812a 6: 32424568 A: 0.35 0.07 (0.01) 1.3×10
-9 0.85 0.01 (0.05) 0.87 
0.07 
(0.01) 2.1×10
-9 19,557 
rs35850753 17: 7578671 T: 0.02 0.22 (0.04) 2.0×10
-8 0.21 0.64 (0.16) 4.5×10
-5 0.24 (0.04) 2.1×10
-10 19,557 
Genome-wide meta-analysis of head circumference scores in pediatric and adult samples as described in Figure 1a; Evidence for 1102 
association was assessed using standard error-weighted fixed effects meta-analysis. Only independent variants (Linkage 1103 
disequilibrium (LD)-r2< 0.2 within +/- 500 kb) reaching nominal evidence for genome-wide significance (p<5x10-8) are shown. 1104 
The adjusted threshold for genome-wide significance is 3.3x10-8, accounting for multiple testing. Detailed information can be 1105 
found in Supplementary Data 1 and 3. 1106 
ars9268812 is in linkage disequilibrium with rs9268668 (r2=0.60) that passes the adjusted genome-wide significance threshold 1107 
within the HC(Pediatric) meta-analysis (Supplementary Data 1).  1108 
Position, base pair position; HC, head circumference; EA, effect allele; EAF, effect allele frequency; β, effect 1109 
estimate; SE standard error; p, p-value; N, sample size; phet , p-value for heterogeneity statistic (based on 1110 
Cochran’s Q-test for heterogeneity).  1111 
 1112 
 1113 
 1114 
  1115 
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Table 2: Novel independent loci for combined intracranial volume and head circumference 1116 
Variant Chr:Pos (b37) EA:EAF 
ICV HC 
 (Pediatric + adult) 
ICV+HC  
(Pediatric + adult) NTotal 
β* 
(SE) p 
β* 
(SE) p 
β* 
(SE) p N 
rs2168812 1: 243777066 A: 0.18 0.05 (0.01) 9.0x10
-6 0.06 (0.01) 1.5x10
-5 0.05 (0.01) 2.3x10
-9 45,458 
rs4513262 2: 10181457 T: 0.21 0.05 (0.01) 7.7x10
-7 0.04 (0.01) 2.3x10
-3 0.05 (0.01) 2.9x10
-8 45,336 
rs41288837 2: 85531116 T: 0.03 -0.10 (0.03) 1.0x10
-4 -0.15 (0.03) 1.6x10
-6 -0.11 (0.02) 7.2x10
-9 43,916 
rs429150a 6: 32075563 T: 0.52 0.04 (0.01) 3.1x10
-5 0.04 (0.01) 1.0x10
-4 0.04 (0.01) 3.9x10
-8 43,122 
rs9271147b 6: 32577385 T: 0.17 0.06 (0.02) 4.3x10
-4 0.07 (0.01) 6.5x10
-8 0.07 (0.01) 4.4x10
-10 30,057 
rs11154343 6: 126412953 T: 0.31 -0.05 (0.01) 1.7x10
-8 -0.03 (0.01) 1.2x10
-2 -0.04 (0.01) 1.0x10
-8 45,458 
rs7808664a 7: 32917550 A: 0.37 -0.04 (0.01) 1.2x10
-6 -0.03 (0.01) 2.0x10
-3 -0.04 (0.01) 3.6x10
-8 45,458 
rs148974918 10: 112033051 T: 0.05 -0.08 (0.02) 9.4x10
-5 -0.1 (0.02) 1.6x10
-5 -0.08 (0.02) 2.4x10
-8 45,458 
rs3217870 12: 4400111 T: 0.62 -0.03 (0.01) 1.0x10
-4 -0.05 (0.01) 7.0x10
-7 -0.04 (0.01) 3.1x10
-9 45,458 
rs2066827 12: 12871099 T: 0.77 0.05 (0.01) 3.9x10
-6 0.05 (0.01) 9.3x10
-5 0.05 (0.01) 5.4x10
-9 38,871 
rs78378222c 17: 7571752 G: 0.02 0.15 (0.04) 1.4x10
-5 0.21 (0.04) 1.5x10
-7 0.17 (0.03) 7.9x10
-11 41,371 
Genome-wide combined meta-analysis of intracranial volume and head circumference scores as described in Figure 1b; 1117 
Evidence for association was assessed using Z-weighted meta-analysis. Standardized estimates were derived as described in the 1118 
Methods. Only independent variants (Linkage disequilibrium (LD)-r2< 0.2 within +/- 500 kb) reaching nominal evidence for 1119 
genome-wide significance (p<5x10-8) are shown. The adjusted threshold for genome-wide significance is 3.3x10-8, accounting 1120 
for multiple testing. Detailed meta-analysis information can be found in Supplementary Data 11. Detailed SNP and gene 1121 
information is given in Supplementary Data 16 and 17.  1122 
ICV - Intracranial volume (ICV) meta-analysis of ENIGMA2 and CHARGE samples, N ≤ 26,577 1123 
HC (Pediatric+adult) - Combined pediatric and adult head circumference meta-analysis, N ≤ 18,881 1124 
Position, base pair position; EA, effect allele; EAF, effect allele frequency; β*, Standardized effect estimate; SE, 1125 
standard error; p, p-value; N, sample size  1126 
a - Passes a nominal threshold for genome-wide significance only (p<5x10-8) 1127 
b - rs9271147 is in linkage disequilibrium with rs9268812 (r2=0.41), a novel GWAS signal from HC 1128 
(Pediatric+adult) (Table 1, Supplementary Data 3) 1129 
c - rs78378222 is in linkage disequilibrium with rs35850753 (r2=0.56), a novel GWAS signal from HC 1130 
(Pediatric+adult) (Table 1, Supplementary Data 3) 1131 
 1132 
 1133 
 1134 
 1135 
 Pediatric HC cohorts Adult HC cohorts Follow-up HC cohort
6 cohorts
Age: 6 to 9 years
 European descent
individuals
Direct and imputed genotypes
(WGS, UK10K/1KG, HRC r1) 
5 cohorts
Age: 16 to 98 years
European descent
individuals
Direct and imputed genotypes
(WGS, UK10K/1KG, HRC r1) 
 
HC (Pediatric + adult)
Fixed-eects meta-analysis
N≤18,881
10,832,869 variants
ICV
Z-weighted meta-analysis
Adams et al. (2016) 
(CHARGE + ENIGMA 2)
N≤26,577
European descent
individuals
Direct and imputed genotypes
(1KG ph1v3) 
9,702,044 variants
HC (Pediatric + adult + follow-up)
Fixed-eects meta-analysis
N≤19,854
2 variants
1 cohort
Age: 50 years
N=973
 European descent
individuals
Direct and imputed genotypes
(1KG ph1v3) 
 
ICV+HC (Pediatric + adult + follow-up)
Z-weighted meta-analysis
N<46,431*
2 variants
ICV+HC (Pediatric + adult)
Z-weighted meta-analysis
N≤45,458
12,124,458 variants
a
b
HC (Pediatric) HC (Adult)
Fixed-eects meta-analysis
N≤10,600 
10,087,845 variants
Fixed-eects meta-analysis
N≤8,281
8,492,682 variants
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